Part, Chapter, Paragraph
1 I, 2. 10. 4| reimbursement and to check product registration. These diverging national
2 II, 5. 2. 3| per 100.000 during 10-year registration in men and women aged 35-
3 II, 5. 3. 2| 5.3.2.1 Cancer Registration~ ~Population-based cancer
4 II, 5. 3. 2| MSs) have national cancer registration coverage, while in other
5 II, 5. 3. 2| other communicable diseases, registration for cancer is not usually
6 II, 5. 3. 2| instance, thanks to cancer registration we know that:~- mesothelioma
7 II, 5. 3. 2| possible solutions for Cancer Registration in the EU~ ~About one hundred
8 II, 5. 3. 2| States have national cancer registration coverage (see above). Yet
9 II, 5. 3. 2| created a paradox: cancer registration and death registration are
10 II, 5. 3. 2| cancer registration and death registration are both statutory, but
11 II, 5. 3. 2| specialised structures for registration are the two main reasons
12 II, 5. 3. 2| national investment for cancer registration is relatively low if we
13 II, 5. 3. 2| low if we consider that registration is essential for basic,
14 II, 5. 3. 2| country.~ ~Support to cancer registration in all Member States is
15 II, 5. 3. 2| Member States make cancer registration a statutory requirement
16 II, 5. 3. 2| for establishing cancer registration in countries where is currently
17 II, 5. 3. 2| registrars, definition of registration guidelines, collection of
18 II, 5. 3. 3| death as obtained from civil registration systems in countries. The
19 II, 5. 3. 3| registered in national vital registration systems, with underlying
20 II, 5. 4. 2| Normally, an HDR involves the registration of individual characteristics,
21 II, 5. 4. 6| States:~ ~· Collection, registration, monitoring and reporting
22 II, 5. 4. 7| primary units for coding and registration. Efforts to achieve this
23 II, 5. 8. 7| from general practitioner registration: what's the difference?
24 II, 5. 11. 3| been rising steadily since registration was introduced in the mid
25 II, 5. 14. 2| communities including sample registration systems, surveillance systems,
26 II, 5. 15. 3| rare diseases subject to systematic registration has been defined by law.
27 II, 7. 3. 4| national definitions and registration practices (Figure 7.10).~ ~
28 II, 9. 1. 1| year.~WHO recommends that registration of fetal deaths begin at
29 II, 9. 1. 1| legal criteria for birth registration and in their inclusion criteria
30 II, 9. 1. 1| lower limit of 500 grams for registration of births, which can create
31 II, 9. 1. 1| Cnattingius S, Bergsjo P (2002): Registration artifacts in international
32 II, 9. 1. 1| trends by social class, registration status, mother's age and
33 II, 9. 1. 2| and in infancy, or extend registration to new diagnoses made during
34 II, 9. 1. 2| and e) practices regarding registration of a baby as a stillbirth
35 II, 9. 1. 2| recent years due to late case registration). This increase is seen
36 II, 9. 1. 2| informed parental consent for registration is logistically difficult
37 II, 9. 1. 2| of Informed Consent for Registration of Congenital Anomalies
38 II, 9. 1. 2| 1.3: Instruction for the Registration of Congenital Anomalies",
39 II, 9. 3. 2| ascertainment (completeness of registration) and case description. Improvement
40 II, 9. 3. 2| Cnattingius S, Bergsjo P (2002): Registration artifacts in international
41 II, 9. 3. 2| trends by social class, registration status, mother's age and
42 III, 10. 2. 1| communities including sample registration systems, surveillance systems,
43 III, 10. 2. 4| Genomics European Network~REACH~Registration, Evaluation, Authorisation
44 III, 10. 3. 2| and Feed products~REACH~Registration, Evaluation, Authorization
45 III, 10. 3. 2| new EU legislation on the Registration, Evaluation and Authorisation
46 III, 10. 3. 2| 2006 the REACH legislation (Registration, Evaluation, Authorization
47 III, 10. 3. 2| chemicals legislation on the Registration, Evaluation and Authorisation
48 III, 10. 4. 2| another primary role in the registration or approval of certain feed
49 III, 10. 4. 5| nineties, although improved registration probably also played a role.
50 III, 10. 5. 2| analysis of Scottish cancer registration. British Journal of Cancer.
51 IV, 11. 5. 6| ethical, protection and registration practices in relation to
52 IV, 12. 2 | and the support of cancer registration. ~ ~Diabetes~ ~Long term
53 IV, 12. 10 | REACH-Directive that harmonises the registration, evaluation, administration
